ATXS
Price
$6.65
Change
+$0.09 (+1.37%)
Updated
Jul 25 closing price
Capitalization
375.29M
14 days until earnings call
BOLT
Price
$6.32
Change
-$0.28 (-4.24%)
Updated
Jul 25 closing price
Capitalization
12.12M
9 days until earnings call
Interact to see
Advertisement

ATXS vs BOLT

Header iconATXS vs BOLT Comparison
Open Charts ATXS vs BOLTBanner chart's image
Astria Therapeutics
Price$6.65
Change+$0.09 (+1.37%)
Volume$117.14K
Capitalization375.29M
Bolt Biotherapeutics
Price$6.32
Change-$0.28 (-4.24%)
Volume$4.46K
Capitalization12.12M
ATXS vs BOLT Comparison Chart in %
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BOLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. BOLT commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a StrongBuy and BOLT is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (ATXS: $6.65 vs. BOLT: $6.32)
Brand notoriety: ATXS and BOLT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 33% vs. BOLT: 13%
Market capitalization -- ATXS: $375.29M vs. BOLT: $12.12M
ATXS [@Biotechnology] is valued at $375.29M. BOLT’s [@Biotechnology] market capitalization is $12.12M. The market cap for tickers in the [@Biotechnology] industry ranges from $313.33B to $0. The average market capitalization across the [@Biotechnology] industry is $2.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileBOLT’s FA Score has 1 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • BOLT’s FA Score: 1 green, 4 red.
According to our system of comparison, both ATXS and BOLT are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 3 TA indicator(s) are bullish while BOLT’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 3 bullish, 5 bearish.
  • BOLT’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, BOLT is a better buy in the short-term than ATXS.

Price Growth

ATXS (@Biotechnology) experienced а +11.39% price change this week, while BOLT (@Biotechnology) price change was +14.29% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +8.35%. For the same industry, the average monthly price growth was +22.71%, and the average quarterly price growth was +45.47%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

BOLT is expected to report earnings on Aug 06, 2025.

Industries' Descriptions

@Biotechnology (+8.35% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ATXS($375M) has a higher market cap than BOLT($12.1M). ATXS YTD gains are higher at: -25.615 vs. BOLT (-40.946). BOLT has higher annual earnings (EBITDA): -61.54M vs. ATXS (-124.4M). ATXS has more cash in the bank: 295M vs. BOLT (38.8M). ATXS has less debt than BOLT: ATXS (5.06M) vs BOLT (24.7M). BOLT has higher revenues than ATXS: BOLT (3.64M) vs ATXS (0).
ATXSBOLTATXS / BOLT
Capitalization375M12.1M3,099%
EBITDA-124.4M-61.54M202%
Gain YTD-25.615-40.94663%
P/E RatioN/AN/A-
Revenue03.64M-
Total Cash295M38.8M760%
Total Debt5.06M24.7M20%
FUNDAMENTALS RATINGS
ATXS: Fundamental Ratings
ATXS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
57
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
50
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ATXSBOLT
RSI
ODDS (%)
Bearish Trend 4 days ago
82%
N/A
Stochastic
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
73%
MACD
ODDS (%)
Bearish Trend 4 days ago
82%
Bullish Trend 4 days ago
74%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
85%
Bullish Trend 4 days ago
80%
Advances
ODDS (%)
Bullish Trend 6 days ago
80%
Bullish Trend 6 days ago
71%
Declines
ODDS (%)
Bearish Trend 18 days ago
90%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
80%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
87%
Bullish Trend 4 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
BOLT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ALNT39.740.46
+1.17%
Allient
BGLC4.900.02
+0.41%
Bionexus Gene Lab Corp
OMC76.48-0.58
-0.75%
Omnicom Group
LFT2.28-0.06
-2.56%
Lument Finance Trust
GPOR168.33-5.02
-2.90%
Gulfport Energy Corp

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with DNLI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+1.37%
DNLI - ATXS
57%
Loosely correlated
-4.47%
CRNX - ATXS
53%
Loosely correlated
+1.91%
XENE - ATXS
52%
Loosely correlated
-2.29%
IDYA - ATXS
52%
Loosely correlated
-1.33%
CGEM - ATXS
51%
Loosely correlated
-1.80%
More

BOLT and

Correlation & Price change

A.I.dvisor tells us that BOLT and ELVN have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that BOLT and ELVN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BOLT
1D Price
Change %
BOLT100%
-4.24%
ELVN - BOLT
31%
Poorly correlated
-3.42%
LEGN - BOLT
31%
Poorly correlated
-1.92%
CLSD - BOLT
31%
Poorly correlated
-7.74%
ATXS - BOLT
30%
Poorly correlated
+1.37%
XENE - BOLT
29%
Poorly correlated
-2.29%
More